2-[[2-[(2-ethylcyclopropyl)methyl]cyclopropyl]methyl]cyclopropaneoctanoic acid methyl ester

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-[[2-[(2-ethylcyclopropyl)methyl]cyclopropyl]methyl]cyclopropaneoctanoic acid methyl ester
• 英文别名: Cyclopropaneoctanoic acid, 2-[[2-[(2-ethylcyclopropyl)methyl]cyclopropyl]methyl]-, methyl ester；methyl 8-[2-[[2-[(2-ethylcyclopropyl)methyl]cyclopropyl]methyl]cyclopropyl]octanoate
• 化学式: C₂₂H₃₈O₂
• 分子量: 334.543
• InChiKey: KDWSWRXUIMELKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-[[2-[(2-ethylcyclopropyl)methyl]cyclopropyl]methyl]cyclopropaneoctanoic acid methyl ester 在 sodium hydride 、 sodium hydroxide 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 、 正己烷 、 四氢呋喃 、 水 为溶剂， 反应 10.5h， 以23%的产率得到1,15-bis[2-({2-[(2-ethylcyclopropyl)methyl]cyclopropyl}methyl)cyclopropyl]pentadecan-8-one
  参考文献：
  名称：

  NOVEL LIPID

  摘要：

  公开号：

  EP3020701B1

文献信息

• [EN] PKC ACTIVATORS AND COMBINATIONS THEREOF<br/>[FR] ACTIVATEURS DE PKC ET DES COMBINAISONS DE CEUX-CI
  申请人：BRNI NEUROSCIENCES INST

  公开号：WO2013071282A1

  公开（公告）日：2013-05-16

  The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

  本公开涉及PKC激活剂及其组合物。本公开进一步涉及其组成物、试剂盒、用途和方法。
• PKC ACTIVATORS AND COMBINATIONS THEREOF
  申请人：BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE

  公开号：US20140315990A1

  公开（公告）日：2014-10-23

  The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

  本公开涉及PKC激活剂及其组合物。本公开进一步涉及其组成物、套件、用途和方法。
• Cationic lipid
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US10731159B2

  公开（公告）日：2020-08-04

  The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

  本发明提供了一种由式（Ia）表示的化合物，作为一种新型阳离子脂质，可形成脂质颗粒，还提供了一种包含该化合物的脂质颗粒。本发明进一步提供了一种含有该脂质颗粒的核酸脂质颗粒，以及一种含有该核酸脂质颗粒作为活性成分的药物组合物。
• STIMULUS-ELICITED GENOMIC PROFILE MARKERS OF A NEURODEGENERATIVE CONDITION
  申请人：Blanchette Rockefeller Neurosciences Institute

  公开号：US20140235496A1

  公开（公告）日：2014-08-21

  The present disclosure is directed to methods of diagnosing a neurodegenerative condition, such as Alzheimer's disease, comprising contacting a cell sample from a subject with at least one stimulus, such as a protein and/or polysaccharide mixture, a protein kinase C activator, an Aβ oligomer, an agent, and combinations thereof; and detecting the expression of at least one gene in the cell sample. Methods may further comprise comparing the expression of the at least one gene in the cell sample to the expression of the same at least one gene in control cells; and determining whether the subject has the neurodegenerative condition (e.g., Alzheimer's disease), wherein a change in the expression of the at least one gene in the cell sample compared to the expression of the same at least one gene in the control cells indicates the subject has the neurodegenerative condition (e.g., Alzheimer's disease).
• CATIONIC LIPID
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20180051285A1

  公开（公告）日：2018-02-22

  The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.